NRSNW
NeuroSense Therapeutics Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$0.01
+4.76%Price chart
Sep 8Sep 16Sep 21Sep 24Sep 29Oct 5Oct 13Oct 19
Key dataOct 19, 2026
Open$0.02
From 52W high−98.76%
Volume6705.00
Market cap$279422.00
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$0.02
From 52W high
−98.76%
Volume
6705.00
Market cap
$279422.00
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.0x
P/E (TTM)
—
RSI (14)
40.7
MomentumView details →
1D Return
+4.76%
YTD Return
−96.61%
Similar companies
Latest newsMore news →
NeuroSense Therapeutics filed a U.S. patent application seeking protection for PrimeC use in traumatic brain injury, including concussion, blast-related brain injury and chronic traumatic encephalopathy.21h agoNeuroSense Therapeutics Ltd. said it has secured a NASDAQ, INC. hearing date, with its shares continuing to trade pending the Panel’s decision.7d agoNeuroSense Therapeutics announced a redesigned, capital-efficient development strategy for its ALS drug PrimeC, including an AI-enabled formulation characterization, a comparative study against edaravone, and an optimized Phase 3 PARAGON trial design, with a New Drug Submission to Health Canada targeted for December 2026.47d ago